Perioperative bridging anticoagulation in patients with atrial fibrillation

New England Journal of Medicine

Volumn 373, Issue 9, 2015, Pages 823-833

  Douketis, James D ^a,b   Spyropoulos, Alex C ^d   Kaatz, Scott ^f   Becker, Richard C ^g   Caprini, Joseph A ^h   Dunn, Andrew S ^e   Garcia, David A ^j   Jacobson, Alan ^k   Jaffer, Amir K ⁱ   Kong, David F ^l   Schulman, Sam ^c   Turpie, Alexander G G ^c   Hasselblad, Vic ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f HURLEY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^k Jerry L Pettis Memorial VA Medical Center   (United States)

^l DUKE CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; CLINICAL TRIAL; ELECTIVE SURGERY; MULTICENTER STUDY; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; ELECTIVE SURGICAL PROCEDURES; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; WARFARIN;

EID: 84938932687     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1501035     Document Type: Article

References (47)

1. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.
2. Piazza G, Goldhaber SZ. Periproce-dural management of the chronically an-ticoagulated patient: critical pathways for bridging therapy. Crit Pathw Cardiol 2003; 2:96-103.
3. Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anti-coagulation. Circulation 2012;126:1573-6.
4. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thrombo-embolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagu-lation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-8.
5. [Erratum, Circulation 2012;126(10):e160.]
6. Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014; 124:3692-8.
7. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368: 2113-24.
8. Schulman S, Hwang HG, Eikelboom J W, Kearon C, Pai M, Delaney J. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost 2014;12:1254-9.
9. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319-26.
10. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-63.
11. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Hae-most 2007;5:2211-8.
12. Halbritter KM, Wawer A, Beyer J, Oet-tler W, Schellong SM. Bridging anticoagu-lation for patients on long-term vitamin-K-antagonists: a prospective 1 year registry of 311 episodes. J Thromb Haemost 2005; 3:2823-5.
13. Spyropoulos AC, Turpie AGG, Dunn AS, et al. Clinical outcomes with unfrac-tionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006;4:1246-52.
14. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83:639-45.
15. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight hepa-rin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119: 2920-7.
16. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Hae-most 2010;8:107-13.
17. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med 2003;163:881-3.
18. BRIDGE Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation 2012; 125(12):e496-e498.
19. Patel JP, Arya R. The current status of bridging anticoagulation. Br J Haematol 2014;164:619-29.
20. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of anti-thrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:Suppl:299S-339S.
21. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Car-diol 2011;57(11):e101-e198.
22. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:Suppl:e326S-e350S.
23. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007;146:184-7.
24. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94:528-31.
25. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003;163:901-8.
26. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-9.
27. Barnard GA. Significance tests for 2 X 2 tables. Biometrika 1947; 34: 123-38.
28. StatXact Version 9 with Cytel Studio. Cambridge, MA: CYTEL Software, 2010.
29. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thrombo-embolic rates. Circulation 2012; 126: 1630-9.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
31. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoag-ulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: substudy of the RE-LY trial. Thromb Haemost 2015; 113:625-32.
32. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131:488-94.
33. Spyropoulos AC. Pro: "Bridging anti-coagulation is needed during warfarin interruption in patients who require elective surgery." Thromb Haemost 2012; 108: 213-6.
34. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8: 884-90.
35. Cheung CC, Martyn A, Campbell N, et al. Predictors of intraoperative hypotension and bradycardia. Am J Med 2015; 128: 532-8.
36. Grip L, Blombäck M, Schulman S. Hypercoagulable state and thromboem-bolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991;12:1225-33.
37. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic-pharmacody-namic considerations. Clin Pharmacoki-net 1996; 30: 300-13.
38. Kosir MA, Schmittinger L, Barno-Winarski L, et al. Prospective double-arm study of fibrinolysis in surgical patients. J Surg Res 1998;74:96-101.
39. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
40. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
41. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64.
42. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-96.
43. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;129:1850-9.
44. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:2084-93.
45. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 2013;1:E115-9.
46. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation-quality and cost implications. Am J Med 2014;127(11):1075.e1-1082.e1.
47. Olesen JB, Sørensen R, Hansen ML, et al. Non-vitamin K antagonist oral anti-coagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europa-ce 2015;17:187-93.